Joan Genescà Ferrer Internal medicine doctor expert in hepatology. Special dedication to advanced liver disease, liver cirrhosis and portal hypertension. Interest in non-invasive methods for the diagnosis and control of liver disease, especially liver elastography. Both clinical and experimental research in animal models of liver disease, including therapeutic studies with nanomedicine. Institutions of which they are part Head of group Liver Diseases Vall Hebron Institut de Recerca Hepatologia General Hospital Twitter Orcid Joan Genescà Ferrer Twitter Orcid Institutions of which they are part Head of group Liver Diseases Vall Hebron Institut de Recerca Hepatologia General Hospital Internal medicine doctor expert in hepatology. Special dedication to advanced liver disease, liver cirrhosis and portal hypertension. Interest in non-invasive methods for the diagnosis and control of liver disease, especially liver elastography. Both clinical and experimental research in animal models of liver disease, including therapeutic studies with nanomedicine.
Projects Spanish Clinical Research Network (SCReN) IP: Inmaculada Fuentes Camps Collaborators: Antonio Moreno Galdó, Spanish Clinical Research Network (SCReN), Ariadna Martín Balcells, Olga Sánchez- Maroto Carrizo, Joan Genescà Ferrer Funding agency: Instituto de Salud Carlos III Funding: 319550 Reference: PT17/0017/0030 Duration: 01/01/2018 - 31/12/2020 LIVERHOPE: SIMVASTATIN AND RIFAXIMIN AS NEW THERAPY FOR PATIENTS WITH DECOMPENSATED CIRRHOSIS IP: - Collaborators: Ester Palacio Gutierrez, Olga Sánchez- Maroto Carrizo, Amaia Latasa Arrazubi, Joan Genescà Ferrer Funding agency: EUROPEAN COMMISSION Funding: 409557 Reference: LIVERHOPE_H2020RTD2016 Duration: 01/01/2017 - 28/02/2023 Sol·licitud d'intensificació per a la dedicació en el projecte "Investigación traslacional en complicaciones de la cirrosis: del modelo experimental a la clínica y viceversa" (PI15/00066). IP: - Collaborators: Joan Genescà Ferrer Funding agency: Instituto de Salud Carlos III Funding: 18000 Reference: INT16/00109 Duration: 31/01/2017 - 31/12/2017 Efectos de la administración de albúmina en pacientes cirròticos con encefalopatia hepática IP: - Collaborators: Joan Genescà Ferrer Funding agency: Instituto de Salud Carlos III Funding: 30000 Reference: INT15/00040 Duration: 01/01/2016 - 31/12/2016 Pagination First page « Previous page ‹ … Page 4 Page 5 Current page 6 Page 7 Page 8 … Next page › Last page »
